A Phase I Dose Escalation Trial of Once Daily Oral Treatment BIBW 2992 Plus Gemcitabine or Docetaxel in Patients With Relapsed or Refractory Solid Tumors.
Observational
Observational Model: Cohort, Time Perspective: Prospective
The primary objective is to determine the maximum tolerated dose (MTD) of oral Afatinib given in combination with gemcitabine or docetaxel in patients with relapsed or refractory tumors
3 weeks
No
Boehringer Ingelheim
Study Chair
Boehringer Ingelheim Pharmaceuticals
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
1200.93
NCT01251653
November 2010
April 2014
Name | Location |
---|